The Hidden Costs of “Good Enough” Extraction

The translational oncology landscape has changed dramatically in the past two decades, and with it, the demands on the laboratories doing this work. Today’s translational oncology workflows require DNA and RNA from the same FFPE tissue section, cell-free DNA from large plasma volumes, and nucleic acids from heterogeneous batches of sample types processed in a single run. The analyte diversity has increased dramatically, and at the same time, the downstream assays interrogating those samples have grown more sensitive. The operational pressures have grown alongside the scientific ones. Labs are processing more samples than ever, but not with proportionally more staff. Same-day extraction to analysis is increasingly the expectation, not the exception. All of that change and complexity lands at the extraction step first.

Scientist holding up an FFPE tissue sample. Such samples are vital for nucleic acid extraction required for retroactive studies.

Extraction has long been treated as the step before the experiment, the part you complete before the real work begins. However, as these pressures on the translational laboratory grow, overlooking potential issues with extraction could be disastrous, particularly for labs working with limited, irreplaceable samples, because pre-analytical variability at the extraction step propagates through every downstream process. When extraction is overlooked, information in a sample can be lost and with it the insight into the biological question your downstream assay is asking.

Continue reading “The Hidden Costs of “Good Enough” Extraction”

Measuring What Matters in Metabolic Research: A Bioluminescent Toolkit

This guest blog post is written by Aisosa Omere, Product Marketing Intern at Promega.

Metabolic diseases fundamentally arise from disrupted cellular communication. In type 2 diabetes, cellular responsiveness to insulin is impaired. Within cancer, tumors alter their metabolic pathways to gain a proliferative advantage. In both conditions, dysfunction extends beyond individual molecules or pathways and involves a complex, interconnected network of metabolites, enzymes, and signaling molecules that dynamically respond to environmental changes. Traditional approaches to studying these networks often required a compromise: stopping experiments, lysing cells, and analyzing the resulting components. Although effective, this method is inherently limited. It captures a snapshot of what was present, rather than how the biology was actually behaving.

That compromise is becoming less necessary. The evolution of bioluminescent tools is changing what is possible. Some allow researchers to watch protein behavior and drug engagement directly in living cells in real time. Others offer faster, more sensitive detection of metabolites at physiologically relevant concentrations, and are compatible enough to run multiple assays from the same experiment, making coordinated, multi-pathway profiling practical in a standard lab setting.

An analysis of eighteen peer-reviewed publications from 2025 and 2026 shows just how quickly these approaches are taking hold across metabolic disease research. What follows explores the tools making this possible and why this shift represents one of the most consequential methodological changes in metabolic disease research in recent years.

Continue reading “Measuring What Matters in Metabolic Research: A Bioluminescent Toolkit”

Advancing Canine Cancer Immunotherapy through One Health Comparative Oncology Research

The Case for Canine Immunotherapy

Cancer does not respect species boundaries. Each year more than four million dogs are diagnosed with cancer (1), making it the leading disease related cause of death in the canine population. Osteosarcoma, lymphoma, mast cell tumors and mammary carcinomas are among the most prevalent (1). In many cases, these tumors in dogs bear striking biological and molecular similarities to their human counterparts.

This convergence is the foundation of the Comparative Oncology (2) framework and One Health Initiatives. Companion pets, like dogs and cats, share our environments, our lifestyles and increasingly our therapeutic challenges. When research advances in veterinary oncology, it can open windows into human disease as well.

Comparative oncology integrates the advances and research of veterinary science. Dog and cat against a background of antibodies.
Comparative oncology integrates the advances and research of veterinary science, especially those of companion animals like dogs and cats, into more general oncology research, advancing the entire field of oncology.

What Veterinary Checkpoint Immunotherapy Brings to Comparative Oncology

Continue reading “Advancing Canine Cancer Immunotherapy through One Health Comparative Oncology Research”

ISO 14001 in Biotech: What It Means for Life Science Researchers

This blog is guest-authored by Corey Meek, Corporate Responsibility Program Manager

Promega has achieved ISO 14001 certification for environmental management systems.

Over the past few years, weโ€™ve noticed that our customers’ procurement teams are increasingly asking us about ISO 14001 certification. As a company that has long set ambitious sustainability goals, we have been heartened to see more labs and life science companies incorporating environmental impact into their planning and purchasing. To support our customers looking for external validation of environmental management, we announced in mid-2025 that Promega Madison has achieved ISO 14001:2015 certification.

ISO 14001 certification goes far beyond reporting and reducing our carbon footprint. It represents how we integrate environmental sustainability across complex operations to achieve ambitious environmental objectives. For scientists evaluating potential suppliers, it signals our commitment to sustainability without compromising the product consistency and reliability your lab depends on.

What is ISO 14001?

ISO 14001 is an internationally recognized standard that defines requirements for environmental management systems. This captures the processes we use to identify, control and reduce our environmental impacts. Unlike regulations that set specific pollution limits, ISO 14001 establishes a framework that includes setting environmental objectives, implementing operational controls, monitoring performance and driving continual improvement. The standard mandates leadership accountability and requires a third-party audit, annual surveillance and recertification every three years.

In practice, this means that we document every significant environmental aspect of our operations, from chemical waste streams in manufacturing to energy consumption in our facilities. We establish controls for each: procedures for handling hazardous materials, protocols for managing wastewater, systems for tracking energy use. We document incidents, investigate root causes, train employees and implement corrective actions to stay on target. Third-party auditors verify annually that these systems are functioning effectively and meeting the requirements of the ISO 14001 standard.

Our certification isnโ€™t a one-time checkbox; itโ€™s a commitment to continual improvement through the same management disciplines used in quality systems. We identify risks and establish operational controls for significant environmental aspects. When issues arise, we use structured nonconformance and corrective action processes.

How Does Environmental Management Connect to Quality and Supply Chain Reliability?

ISO 14001 and ISO 9001 (Quality Management Systems) share fundamental processes such as document control, training and competence requirements, change control procedures, nonconformance and corrective action (NC/CAPA) systems, equipment controls and internal audit protocols.

At Promega, all our major manufacturing and R&D sites are covered by both certifications. When we evaluate changes through our change control process, we assess both quality and environmental implications simultaneously. The partnership between our quality assurance and environmental management teams strengthens both systems and reduces operational blind spots.

This integration is important because environmental management doesnโ€™t operate separately from product development and manufacturing. Hazardous materials handling, for example, requires environmental compliance, worker safety protocols and quality control simultaneously. The discipline required for ISO 14001 certification directly supports the manufacturing consistency researchers depend on for reproducible results. Environmental incident management and emergency response protocols reduce disruptions that could affect product availability and distribution.

What sustainability metrics are we measuring?

 ISO 14001 certification requires us to establish measurable environmental objectives and monitor our performance against them. Our organizational objectives include regulatory compliance verification, greenhouse gas emissions reduction, water consumption reduction and waste reduction. For example, weโ€™re currently managing 87% of our hazardous waste through reclamation and recovery methods.

These objectives are monitored through multiple mechanisms: energy consumption and natural gas usage tracking, environmental incident documentation and analysis, internal and external compliance inspections, third-party assessment, and regular management review of performance data.

These quantifiable objectives are more powerful than aspirational statements. Annual third-party audits provide independent verification of our environmental performance. When procurement teams evaluate suppliers, they can choose to rely on ISO 14001 certification rather than conducting their own environmental audits. Most importantly, we approach sustainability strategically and responsibly by building robust processes rather than looking for quick wins. This means our gains are scalable, while safeguarding the consistency researchers using Promega products need for reproducible results.

ISO 14001 at Promega: Looking ahead

This certification requires us to demonstrate through third-party audits that our environmental management systems are effective over time. By focusing on measurable objectives and continuous improvement, weโ€™re reducing our environmental impact in responsible ways that align with established standards and expectations.

In upcoming articles, weโ€™ll explore how these ISO 14001 principles apply to processes and operations at Promega. Environmental management isnโ€™t an isolated program; itโ€™s infused in everything we do, from early product development to shipping of ready-to-use kits. As sustainability becomes increasingly important in procurement decisions, weโ€™re committed to the environmental transparency and operational discipline that support your research goals.


Corey Meek is the Corporate Responsibility Program Manager at Promega.

Learn more about Promega Corporate Responsibility at https://www.promega.com/corporate-responsibility-csr/


When Cancer Research Depends on Quality RNA: Maxwellยฎ RSC in the Lab

Reliable molecular research starts with reliable sample preparation. Two recently published cancer biology studies illustrate this well, and both studies relied on the Maxwellยฎ RSC platform to extract RNA from formalin-fixed, paraffin-embedded (FFPE) tissue, the archival format that makes up the bulk of clinical pathology material.

With Maxwell Instruments and chemistries for FFPE samples, RNA quality is suitable for many critical assays.

Mapping Molecular Targets in a Rare Thyroid Cancer

A 2025 study published in Endocrine Pathology focused on poorly differentiated thyroid carcinoma (PDTC), a rare and aggressive thyroid cancer subtype with limited treatment options once surgery is no longer curative (1). The research question was straightforward but clinically urgent: how many PDTC cases harbor mutations that could be targeted with existing or emerging therapies?

Continue reading “When Cancer Research Depends on Quality RNA: Maxwellยฎ RSC in the Lab”

Accelerating Drug Discovery at Grove Biopharma with MyGloยฎ and ProNectยฎ

At Grove Biopharma, the R&D team is advancing a rational design approach to drug discovery. Their Bionic Biologicsโ„ข Platform assembles custom-engineered peptides to target intracellular protein-protein interactions into stable, potent, cell permeable therapeutics. By combining the precision of biologics with the efficiency of synthesizing small molecules, Grove accelerates lead generation and optimization.

Groveโ€™s technology enables targeting key proteins involved in cancer and neurodegenerative diseases for which effective therapeutics have historically been difficult to develop. Their candidate molecules focus on important targets such as the Androgen Receptor splice variant, SHOC2 within the RAS/RAF pathway, the MYC-regulator WDR5, a Tau isoform relevant to Alzheimerโ€™s Disease, and the Keap1-Nrf2 interaction associated with neurodegeneration. These programs have made significant progress and now represent some of the most advanced agents in their pipeline.

Continue reading “Accelerating Drug Discovery at Grove Biopharma with MyGloยฎ and ProNectยฎ”

From Mt. Fuji to the Lab Bench: A UW-Madison Student’s Summer in Japan

This blog is guest-written by Lucy Kneeley, a 2025 recipient of the Promega International Internship Scholarship. The scholarship is granted annually to University of Wisconsin-Madison students traveling abroad for internship opportunities.

Lucy Kneeley poses at the summit of Mt Fuji.

Last summer, I completed an internship at the Institute of Science Tokyo in the lab of Professor Satoshi Kaneko. As someone who has never been out of the United States for more than a 10-day vacation, I gained a lot of valuable communication experience by navigating a language barrier, but more importantly, across different social norms. Immersing myself in a new country with a new language and culture has led me to think differently and realize how quickly a group of strangers can become a new community. By the end of the three months, I had formed a network of colleagues and friends at the university and within the local community.

Continue reading “From Mt. Fuji to the Lab Bench: A UW-Madison Student’s Summer in Japan”

Promega Fc Effector Assays: Measure Every Mechanism

This post is written by Kai Hillman, PhD, Promega Corporation.

Every day, scientists push the boundaries of whatโ€™s possible with monoclonal antibodies (mAbs)โ€”from targeting cancer cells to calming autoimmune-driven inflammation. These therapies rely not only on binding but on engineering the desired immune response. The suite of Promega Fc Effector Assays helps you understand these interactions from receptor binding and function, through bridging studies. With consistency, sensitivity, and scalability, these assays support teams from early discovery through lot release.

This article draws on real-world publications and product insights to show how Promega assays are powering next-generation immunotherapiesโ€”and redefining how we measure immune engagement.

Schematic diagramming the suite of Promega Fc effector assays in one seamless workflow to support antibody development across the pipeline.
Figure 1. Promega delivers the most comprehensive suite of Fc effector assays in one seamless workflow to support antibody development across the pipeline.
Continue reading “Promega Fc Effector Assays: Measure Every Mechanism”

Residence Time: The Impact of Binding Kinetics on Compound-Target Interactions

This blog was written by guest contributor Tian Yang, Associate Product Manager, Promega, in collaboration with Kristin Huwiler, Manager, Small Molecule Drug Discovery, Promega.

During the development of chemical probes or small-molecule drugs, compound affinity (Kd) or potency (IC50) is used to characterize compound-target interactions, to guide structure-activity relationship analysis and lead optimization and to assess compound selectivity.

However, neither parameter provides information on how quickly a compound engages with and dissociates from the target. The dissociation constant Kd reflects the relative concentrations of unbound and bound state of the compound at thermodynamic equilibrium, and while IC50 is an empirical metric that measures the concentration at which a biochemical or cellular process is reduced to half of the maximum value, IC50 values are typically determined when the process is assumed to be at equilibrium or steady-state. For a closed system, like cells in a culture dish, these thermodynamic parameters are quite informative. In an open system like the human body, where compound-target interactions often do not reach equilibrium, the kinetic parameters, in addition to the thermodynamic parameters, are needed to better understand and characterize compound target engagement over time (1,2).

Continue reading “Residence Time: The Impact of Binding Kinetics on Compound-Target Interactions”

Bringing Industry-Relevant Lab Experience to Undergraduate Life Sciences Majors with MyGloยฎ

When Dr. Rebecca Miles retired from her 25-year career in pharmaceutical research at Eli Lilly, she refocused her passion for science on a new challenge. Having worked her way from the bench to Senior Director, she knew first-hand the technical skills required to successfully advance genetic medicine programs. Now, she leverages her industry experience and the latest technologies at Taylor University, a liberal arts institution in Indiana known for its strong emphasis on education and practical training for studentsโ€™ future careers. As a Visiting Assistant Professor of Biology, Dr. Miles trains her students to develop real-world skills and provides them exposure to technologies that impacted her own career. โ€œI wanted to redesign the lab so that students could come out of the semester with some job skills if they wanted to be a technician in a lab,โ€ she explains.

Dr. Rebecca Miles undergraduate class with their MyGloยฎ

Teaching Students Modern Technologies

Dr. Miles structures her lab courses to incorporate techniques that scientists would routinely use in an industry setting. Students learn cell culture, plating, luminescent assays, and data analysis in ways that mirror the workflows used in biotech and pharmaceutical labs. She encourages her students to analyze their raw data to learn how the calculations work. โ€œI want the students to calculate it in Excel and do it themselves and see the standard deviation,โ€ she says.

Continue reading “Bringing Industry-Relevant Lab Experience to Undergraduate Life Sciences Majors with MyGloยฎ”